Loyal is a San Francisco clinical-stage veterinary biotech developing the first FDA-track drugs designed to extend the healthy lifespan of dogs. Its lead candidate, LOY-002, is a beef-flavored daily pill for senior dogs that targets metabolic dysfunction in aging. In 2023 it became the first company to receive an FDA acceptance that a drug can be developed to extend lifespan itself - in any species.
Peter Fedichev is a theoretical physicist turned longevity entrepreneur who co-founded Gero, a biotech AI company applying physics-based generative AI models to crack the root causes of aging. A former top-2 cited Russian physicist under 35, he traded quantum gases for aging clocks, building a platform that predicted biological age from wearable data before it was fashionable, secured a Pfizer collaboration, and landed a potential $250M deal with Chugai Pharmaceutical (Roche Group) in 2025 - all while publishing over 75 scientific papers and winning a $10,000 prize for winning a public debate on defeating aging.